Chairs

Cheryl Ho, MD, FRCP(C)

Clinical Assistant Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Cheryl Ho is a clinical assistant professor at the University of British Columbia a medical oncologist at BC Cancer.

She is currently the provincial systemic chair for head and neck malignancies.

She completed medical school and internal medicine training at the University of Western Ontario.

She is a graduate of the BC Cancer Agency Medical Oncology program and completed a fellowship in Thoracic Oncology at University of California, Davis.

Her current practice focuses on the treatment of thoracic and head and neck malignancies.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Randeep Sangha, MD, FRCPC

Medical Oncologist, Cross Cancer Institute
Assistant Professor, University of Alberta
Edmonton, AB

Dr. Sangha is an Associate Professor in the Department of Oncology at the University of Alberta and Medical Oncologist at the Cross Cancer Institute, Edmonton, AB. He is the Provincial Lead for the Alberta Lung Cancer Program.

Dr. Sangha received his medical degree at the University of Alberta and subsequently specialized in Internal Medicine and Medical Oncology. He completed two years of post-fellowship training in thoracic oncology at the University of California, Davis Comprehensive Cancer Center.

His academic, clinical, and educational activities revolve around thoracic and hematological malignancies. He is also experienced in Investigational New Drug (Phase I) development and is actively involved in the Phase I clinical trials program at the Cross Cancer Institute.

Faculty

Penelope Bradbury, MB, BCh, FRACP, MD (UK)

Associate Professor, Department of Medicine, University of Toronto
Associate Professor, Department of Oncology, Queen’s University
Medical oncologist, Princess Margaret Cancer Centre
Toronto, ON

Penelope Bradbury is a staff medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada; Associate Professor, Department of Medicine, University of Toronto, and adjunct Associate Professor within the Department of Oncology at Queen’s University, Kingston, Canada. She has a research interest in the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology and is the current chair of the Canadian Cancer Trials Group Thoracic Disease Site Committee.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Martin Robert Chasen, MBChB, FCP(SA), MPhil(Pall Med)

Associate Professor, Division of Palliative Care, University of Ottawa
Medical Director, Palliative Care,
William Osler Health System
Medical Director, Palliative Rehabilitation, Élisabeth Bruyère Hospital
Brampton, ON

Dr. Martin Chasen is currently the Medical Director of Palliative Care, at William Osler Health System in Brampton. He was previously Medical Director, Palliative Care, at The Ottawa Hospital Cancer Centre and the Palliative Rehabilitation Program at Élisabeth Bruyère Hospital, Ottawa.

Dr. Chasen, born in Pretoria, South Africa completed his undergraduate training in medicine and surgery at the University of Pretoria in 1983, later obtaining a specialist degree in Internal Medicine and Medical Oncology and Master of Philosophy (Palliative Medicine) at the University of Cape Town, South Africa. He is a founding member of the palliative care working group European Society of Medical Oncology and faculty member of ESMO education. In 2009, Dr. Chasen, was Team Leader and Physician, Cancer Nutrition & Rehabilitation Program at McGill University Hospital Complex obtained “Supra regionale de niveau 3” status for the PQCCC.  In 2013, Dr. Chasen and the team at Ottawa Hospital cancer centre achieved ESMO Designated Centre of Integrated Oncology and Palliative care.

He currently holds professorships at the Universities of Toronto, McMaster, Ottawa and McGill. He recently received the Elizabeth J Latimer Prize in Palliative Care from Mc Master University.

He has in excess of 100 peer reviewed publications, abstracts and book chapters. Dr. Chasen is the principle investigator of CIHR (Canadian Institutes of Health Research). This MENAC (The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia), trial will investigate the addition of the multimodal intervention for patients receiving standard chemotherapy for metastatic cancer. He was also one of the chief investigators for the initial clinical trials on the use of Rolapitant-a novel NKI inhibitor in the treatment of chemo therapy induced nausea and vomiting.

Dr. Chasen has lectured nationally and internationally on rehabilitation of patients with cancer, approaches to treatment of patients with cachexia, chemotherapy induced nausea and vomiting, survivorship and symptom relief.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Negar Chooback MD, FRCPC

Assistant Professor
Dept. of Oncology, School of Medicine
Queens University
Kingston, ON

Dr. Chooback received her bachelor of science in molecular genetics at University of Toronto. She then attended Ross Medical School and completed a specialty in internal medicine and chief year in the United states at Yale affiliated Norwalk Hospital.

Dr. Chooback attended Queen’s University for medical oncology training and BC Cancer for thoracic oncology training with Cheryl Ho.

Dr. Chooback has been practicing in Belleville/Kingston since 2017 as a medical oncologist focusing in lung/gi and melanoma.

Harry de Koning, MD PhD

Deputy Head and Professor of Public Health & Screening Evaluation
Dept. of Public Health, Erasmus MC University Medical Center
Rotterdam, Netherlands

I am Deputy Head and Professor of Public Health & Screening Evaluation, Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

My major scientific contributions are in the areas of (1) designing, running and evaluating (often large-scale) multidisciplinary population-based randomized controlled screening trials to establish the efficacy of screening, (2) evaluating active (inter-)national screening programs and clinical tests to establish effectiveness and (3) guiding public health policies on screening and primary prevention using predictions of favourable and unfavourable effects and the cost of interventions, based on micro-simulation modelling of the natural history of disease, risk-prediction modelling and cost-effectiveness and cost-utility analyses. Our multidisciplinary and international research results in recommendations on whether or not to introduce screening, surveillance or other preventive interventions for specific diseases and on policy decisions to introduce it in specific ways, either at population level or in (high risk) patients.

I am PI of the ROBINSCA trial through an Advanced Researcher Grant (2011), to assess the (cost-) effectiveness of screening for cardiovascular disease. I am PI of the NELSN lung cancer screening trial.

We are further responsible for the monitoring and evaluation of the Dutch Breast, Cervical and Colorectal Cancer Screening Program, and presently have HORIZON2020-projects to evaluate breast, cervical and colorectal cancer screening in Europe (coördinator), and evaluate (and implement) vision and hearing screening in Europe (substitute coördinator). We are co-PI in 7 CISNET (NIH/NCI-funded) projects, aimed at modelling and predicting the impact of interventions in breast, prostate, lung, colorectal, oesophageal, colorectal and cervical cancer. These have led to substantial influences in policy making. Perhaps, most prominently our recent analyses on lung cancer screening for the USPSTF, which have led to insurance coverage of low-dose CT screening according to our recommended eligibility in the US.

Marina Chiara Garassino, MD

Medical Oncologist
Chief, Medical Thoracic Oncology Unit
Department of Medical Oncology and Hematology
Istituto Nazionale dei Tumori di Milano
Milan, Italy

Dr. Marina Chiara Garassino is the Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milan, Italy. She leads the strategy for clinical and translational research in advanced and locally advanced NSCLC, SCLC, mesothelioma and thymic malignancies.
Istituto Nazionale dei Tumori in Milan is the most important comprehensive cancer in Italy and one of the most important in Europe.

As a medical oncologist, She has done research in precision medicine and in immuno-oncology. Her main research interests have been mainly development of new drugs and therapeutical strategies and biomarkers. She has contributed to over 120 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and has delivered many presentations at international congresses including AACR, ASCO, ECCO, ESMO, WCLC.

Her education includes a degree (110/110 cum laude) and further specialization in Medical Oncology (70/70 cum laude) at Università degli Studi in Milan. She achieved a Master Degree in Oncology management at University of Economics “Luigi Bocconi”. I completed her training with an ESMO Clinical fellowship in 2009 at Christie’s Hospital in Manchester (UK). She was a member of the EMA SAG (Scientific Advisory Group).

She was able to attract competitive grants (1 TRANSCAN, 2 AIFA, 2 AIRC IG, 1 BERLUCCHI, 2 BRI) as Principal Investigator for over 10 milion euros and she was co-investigator in many others (AIRC, CARIPLO, AIFA).

She is serving as ESMO Council member as the Chair of the National Societies Committee. She was the ESMO National Representative for Italy for 5 years (2011-2017) and she’s serving on several ESMO Committees (Public Policy extended Committee, Press Committee, Women for Oncology Committee, Lung Cancer faculty, Membership Committee). She used to be an active member of the Young Oncologist Committee. She’s serving on both ESMO, WCLC and ASCO annual congress Lung Cancer Track (2019).
She’s the founder and president of Women for Oncology Italy.

Meredith Giuliani MBBS, MEd, FRCPC

Associate Professor in the University of Toronto
Department of Radiation Oncology
Medical Director of Education for Princess Margaret Cancer Centre
Toronto, ON

Dr. Meredith Giuliani is an Associate Professor in the University of Toronto, Department of Radiation Oncology and the Medical Director of Education for Princess Margaret Cancer Centre. Her research interests include the influence of globalization on medical education and outcomes research in lung cancer.

Kyle Grant, MD, MHSc, FRCSC

Clinical Instructor, Division of Thoracic Surgery
University of British Columbia
Vancouver, BC

Dr. Kyle Grant is a Thoracic Surgeon at Vancouver General Hospital.  He completed his medical school training and General Surgery residency at the University of Manitoba.  He subsequently completed his Thoracic Surgery Fellowship at the University of British Columbia and also holds a Masters Degree from the School of Population and Public Health at UBC.  His interests are Thoracic Oncology and Minimally Invasive Thoracic Surgery.

Dr. Desiree Hao

Associate Professor of Medicine, University of Calgary’s Cumming School of Medicine
Medical Oncologist, Tom Baker Cancer Centre (TBCC)
Calgary, AB

Dr. Hao is a medical oncologist at the Tom Baker Cancer Centre (TBCC) and
Associate Professor of Medicine at the University of Calgary’s Cumming
School of Medicine where she is involved in both the Thoracic as well as
Head and Neck Tumour Groups. . She completed her Medical Doctorate at
Queen’s University in Kingston, Internal Medicine residency in Calgary,
Medical Oncology training in Ottawa, and a Clinical Research Fellowship in
cancer drug development at the Institute for Drug Development, Cancer
Therapy & Research Centre in San Antonio, Texas.

Her research interests includes both clinical and translational work. She
has a longstanding commitment serving on the Health Research Ethics Board of
Alberta – Cancer Committee and also has served on the executive the Canadian
Association of Medical Oncologists (CAMO) for over 3 years, currently in the
role of Vice-President and chair of the Human Resources subcommittee.

David S.Hong MD

Professor
Deputy Chair of the Dept of Investigational Cancer Therapeutics [A Phase I Program]
Division of Cancer Medicine
Associate Vice President of Clinical Research
University of Texas M.D. Anderson Cancer Center
Houston, TX

Dr. David S. Hong is a Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center.

Dr. Hong was instrumental in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1200 patients enrolled in clinical trials in FY2018 and over 228 active ongoing clinical trials.

Dr. Hong has been the Principal Investigator of over 100 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute.

He has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib,and  larotrectinib that have led to FDA approval.

He is an expert on c-Met, NTRK, and KRAS and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.

Doris Howell, RN, PhD

Senior Scientist, Princess Margaret Cancer Centre
Toronto, ON

Dr. Doris Howell RN, PhD, is a PhD graduate of the Department of Health Services and Outcomes Research, Institute for Health Policy Management and Evaluation, University of Toronto.

Senior Scientist in Division of Supportive Care, Princess Margaret Cancer Research Institute & Professor (status), Lawrence S. Bloomberg Faculty of Nursing, Cross-appointed to the Institute for Health Policy Management and Evaluation (IHPME) University of Toronto, Toronto, ON. Associate Scientist, ELLICSR Wellness and Cancer Survivorship Centre, Princess Margaret Cancer Center. Past RBC Chair, Oncology Nursing Research and Education and Co-Director, the Ontario Patient Symptoms and Toxicity Research Unit, Princess Margaret Cancer Centre, & Affiliate Scientist, Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, ON.

Dr. Howell’s program of research is focused on mitigating cancer morbidity and optimizing “whole-person” health care for individuals with cancer to live well with and beyond cancer. She conducts clinical trials to test effects of self-management support and e-health interventions on activation of cancer patients and survivors in self-management to reduce severity of complex symptoms (dyspnea, fatigue, pain); and testing of patient reported outcomes for precise measurement of “whole person” impact of cancer and treatment across the continuum.

PhD graduate of the Department of Health Services and Outcomes Research, Institute for Health Policy Management and Evaluation, University of Toronto.
Senior Scientist in Division of Supportive Care, Princess Margaret Cancer Research Institute & Professor (status), Lawrence S. Bloomberg Faculty of Nursing, Cross-appointed to the Institute for Health Policy Management and Evaluation (IHPME) University of Toronto, Toronto, ON. Associate Scientist, ELLICSR Wellness and Cancer Survivorship Centre, Princess Margaret Cancer Center. Past RBC Chair, Oncology Nursing Research and Education and Co-Director, the Ontario Patient Symptoms and Toxicity Research Unit, Princess Margaret Cancer Centre, & Affiliate Scientist, Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, ON.

Dr. Howell’s program of research is focused on mitigating cancer morbidity and optimizing “whole-person” health care for individuals with cancer to live well with and beyond cancer. She conducts clinical trials to test effects of self-management support and e-health interventions on activation of cancer patients and survivors in self-management to reduce severity of complex symptoms (dyspnea, fatigue, pain); and testing of patient reported outcomes for precise measurement of “whole person” impact of cancer and treatment across the continuum.

Puneeth Iyengar, MD, PhD

Assistant Professor, Department of Radiation Oncology
UT Southwestern Medical Center
Dallas, TX

Understanding how tumors respond to radiation has been a lifelong process for Puneeth Iyengar, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern Medical Center. He began testing theories in school science fairs as an adolescent growing up in Louisiana. Studying at MIT furthered his interest in the biologic and engineering aspects of medicine, and he earned a bachelor of science degree in biology before receiving his M.D./Ph.D. degrees from Albert Einstein College of Medicine in New York in 2005. With medical school came a better understanding of cancer biology that led Dr. Iyengar to pursue an internship and residency at MD Anderson Cancer Center in Houston, where he honed his clinical skills.

Dr. Iyengar ultimately chose UT Southwestern as the academic medical center where he wanted to

As a key member of the radiation oncology team at UT Southwestern, Dr. Iyengar has two main roles: He is an expert in treating lung cancer patients with radiation. He also leads a research lab with two missions – discovering how lung tumors become therapeutically resistant and understanding the basic mechanisms of cancer cachexia, a wasting process of the body that’s associated with certain types of tumors, primarily lung and gastrointestinal tumors.

Kevin Jao, MD, MSc, FRCPC


Adjunct Professor
Université de Montréal
Hemato-oncologist
Hôpital du Sacré Coeur de Montréal
Montréal, QC

Dr Jao is an adjunct professor at the Université de Montréal and a hemato-oncologist at the Hôpital du Sacré Coeur de Montréal. He is the medical oncology lead of the thoracic oncology team.

He has a master’s degree in Immunology and HIV from McGill University. He went on to obtain his medical degree from the Université de Montréal, and specialized in internal medicine, hematology and medical oncology. He completed a fellowship in thoracic oncology at the Princess Margaret Cancer Center.

He is the current director of research in hematology and oncology at Sacré Coeur Hospital.

Stephen Lam, MD, FRCPC

Professor of Medicine, Respiratory Division, UBC
Chair, Lung Tumour Group, BC Cancer
Vancouver, BC

Dr. Lam is Professor of Medicine at UBC in the Respiratory Division. He is currently Chair of the Lung Tumour Group and directs the MDS-Rix Early Lung Cancer Detection and Translational Research Program at  BC Cancer . He is a Distinguished Scientist in the Department of Integrative Oncology at the BC Cancer Research Centre. Dr. Lam’s research interest is in early detection, chemo prevention, endoscopic diagnosis and treatment of lung cancer. He was the recipient of the Joseph Cullen Award for life – time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer and the UBC Killam Award.

 Philippe Lambin, MD, PhD

Professor, Precision Medicine
University of Maastricht
Maastricht, Netherlands

Philippe Lambin is a Clinician, Radiation Oncologist, “ERC advanced & ERC PoC grant laureate” from 2016 and pioneer in translational research with a focus on tumour hypoxia and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Precision Medicine) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 461 peer reviewed scientific papers (Hirsch Index: 64 scopus 24-04-2017, 87 Google scholar), co-inventor of more than 18 patents (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 50 completed PhD’s (2 with cum laude).

More recently, his interests have been directed towards hypoxia targeting, Hypoxia Activated Prodrugs, during immunotherapy and the development of a “treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. The website he launched, www.predictcancer.org, with validated predictive models has had more than 20.000 visitors from more than 133 countries.

Scott Laurie, MD FRCPC

Associate Professor of Medicine, University of Ottawa
Division of Medical Oncology
Ottawa, ON

Dr. Scott Laurie received his MD from the University of Ottawa in 1994, and is certified in Internal Medicine and Medical Oncology. He completed a fellowship in Thoracic Oncology at the Memorial Sloan-Kettering Cancer Center in New York in 2000, and subsequently joined on staff at the Ottawa Hospital Cancer Centre. He is an Associate Professor at the University of Ottawa. His research interests are thoracic malignancies, salivary gland malignancies, and investigational new drugs. He has been the principal investigator of several multicenter phase II and III clinical trials. He is the current disease site chair of the Investigational New Drug committee of the NCIC Clinical Trials Group and sites on the Lung Disease site executive.

Alexander L. Lee, MD, MSc, SC, FRCSC

Surgeon
Vancouver Thoracic Surgery
UBC Director Thoracic PGME (Residency Program Director)
Clinical Assistant Professor
University of British Columbia
Vancouver, BC

I went to the University of Western Ontario for my M.D. I received the Star of Courage from the Governor General of Canada in 1995.

I completed my surgical training at the University of Western Ontario and the London Health Sciences Centre in Cardiac Surgery and Thoracic Surgery. I received Royal College certification for Cardiac Surgery in 2005, and for Thoracic Surgery in 2006.

My area of expertise is Minimally Invasive Thoracic Surgery, i.e. Advanced Laparoscopic & Thoracoscopic Surgery for Thoracic Oncology and Benign Diseases of the Foregut.

In January 2017, I joined the Vancouver Coastal Health Thoracic Surgery Division, and the University of British Columbia.

I am the Director of the UBC Thoracic Surgery Residency Program and the Director of the UBC Surgical Foundations Residency Program.

At Vancouver Coastal Health, I am actively involved in Physician Engagement. I am on the board of the Vancouver Physician Staff Association (VPSA), and the Vancouver Medical, Dental and Allied Staff Association. I am a member of the VPSA Engagement Working Group, and the VPSA Diversity, Equity, & Inclusion Working Group. I lead the VPSA Talent Management & Succession Planning Working Group.

I am the Vice-President of the BC Chest Surgery Association, and I am the Thoracic Surgery Section Representative at Doctors of BC.

Anna L. McGuire MD, MSc, FRCSC

Thoracic Surgeon, Vancouver Coastal Health
Clinical Assistant Professor, University of British Columbia
Vancouver, BC

Dr. McGuire is a thoracic surgeon and researcher with specialty interests in lung cancer, minimally invasive surgery, diseases of the thymus and other surgical diseases of the chest.

Her research focuses on lung cancer including genomic biomarkers, and thoracic surgical epidemiology. She is an emerging early career surgeon scientist with publications in high impact journals (The Journal of Thoracic and Cardiovascular Surgery).

 After graduating from the University of Toronto School of Medicine, Dr. McGuire completed her general surgery residency at Queens University, thoracic surgery residency and advanced thoracic surgery fellowship in our nations capitol at the University of Ottawa, followed by her Masters of Science in Clinical Epidemiology with the University of London (LSHTM). Since this time, she has been on faculty at the University of British Columbia and Vancouver General Hospital, as a Royal College of Physicians and Surgeons of Canada board certified academic thoracic surgeon.

Leslie Markin, RN

Clinical Trials Nurse, BC Cancer
Vancouver, BC

Leslie Markin is a Clinical Trials Nurse Coordinator for the Lung Tumor Group at BC Cancer in Vancouver, Canada. She graduated from University of Alberta Hospital School of Nursing and previously worked in ER and Ambulatory Care Chemotherapy Unit.

Michael Mulligan, MD

Chief, Division of Cardiothoracic Surgery
UW Medicine
Seattle, WA

Dr. Mulligan has spent his whole career on the faculty here at UW, first being recruited to lead the lung transplant program, and for the past 6 years serving as Chief of the Section of General Thoracic Surgery. He is a master clinical surgeon with expertise in the surgical management of end-stage lung disease including pulmonary thromboendarterectomy, lung volume reduction surgery, and lung transplantation. He has established the second VA lung transplant program, serving our veterans with lung disease, and established and leads the adult ECMO program at UWMC.

Dr. Mulligan is also an established surgeon scientist, with an NIH funded basic science lab that has conducted important research on lung ischemia reperfusion and lung allograft dysfunction. He has served in a number of important leadership roles inside UW, as well as nationally and internationally. Dr. Mulligan was elected to serve as an At-Large Member of the UWP Board. He leads the Minimally Invasive Thoracic Surgery Program and the Cardiothoracic Surgery Research Program and serves on numerous committees for UWMC and UW Medicine. He has served as the Region 6 Councilor for UNOS, Chair of repeating Critical Care Symposiums at STS and AATS, and recently was elected and served as President of the Western Thoracic Surgical Association. He is a nationally and internationally recognized leader in cardiothoracic surgery and has committed his whole career to elevating the care of patients with cardiothoracic disease at UW Medicine.

Renelle Myers MD, FRCPC

Interventional Respirologist, BC Cancer
Vancouver, BC

Renelle Myers is an interventional respirologist at BCCA.  She completed internal medicine and respirology training at the University of Manitoba and Interventional Pulmonary training at Beth Deaconess Center, Harvard University.  She is also cross appointed between respirology and thoracic surgery at Vancouver general hospital.

She is a member of the Canadian Partnership Against Cancer tobacco cessation network and the program lead for the implementation of smoking cessation at BCCA.  

Jason R. Pantarotto, MD, FRCPC

Chief, Division of Radiation Oncology
Assistant Professor, University of Ottawa
Ottawa, ON

Dr. Jason R. Pantarotto is Head of the Radiation Medicine Program at The Ottawa Hospital and Division Head for Radiation Oncology at the University of Ottawa. His education includes a degree in Applied Science from Queen’s University, a medical degree from Western University, a residency in Radiation Oncology from the University of Ottawa and a fellowship at the VU University Medical Centre in Amsterdam, The Netherlands. He joined The Ottawa Hospital in 2008 and is an Associate Professor.

Dr. Pantarotto has published on ablative radiotherapy for chest and abdominal tumours, advanced radiotherapy techniques for moving targets and factors related to process flow within radiation medicine. He has been an active participant in transforming cancer care in Ottawa since 2013, with a focus on lung cancer process flow. Dr. Pantarotto is a graduate of the Physician Leadership Development Program at the Schulich School of Business

Dave Raben, MD, FASTRO

Professor, Dept of Radiation Oncology
University of Colorado, Anschutz Medical Campus
PDO, Genentech
Aurora, CO

David Raben, MD, FASTRO is a board-certified radiation oncologist and currently is leading efforts in late stage solid tumor development at Genentech in areas that include lung, head and neck, skin and rare cancers. He received his undergraduate degree at Duke University (1981-1985) and his medical degree from Wake Forest University Health Sciences Center (1985-1990). Residency training in radiation oncology was conducted at the John Hopkins Hospital (1991-1994). He took his initial faculty position at the University of Alabama at Birmingham from 1994-1998 heading the GI tumor working group and receiving an ACS translational oncology grant to study use of anti-EGFR strategies against brain tumors. He joined the faculty at the University of Colorado in 1998, an NCI-designated Comprehensive Cancer Center (UCCC) and was a member of the Lung, HN Cancers Program of the UCCC. Professor Raben has extensive expertise in the management of HNC, Lung, Prostate and Bladder cancer. He recently reported on the first Phase I clinical trial in the US combining an oral DNA repair inhibitor Olaparib (PARP inhibitor) with cetuximab and radiation for heavy smokers when combined with intensity modulated radiation (IMRT). Finally, he has served as a co-investigator on a PCORI grant evaluating symptom evaluation and intervention for underserved patients with HN and lung cancer.

From a research perspective, his focus has been on laboratory discoveries related to radiation interactions with immune enabling drugs as well as DNA repair inhibitors and agents that affect TGFb signaling in HNC. He was a co-investigator on an RO1 funded grant that investigates combinations of anti-TGFb and checkpoint inhibition in orthotopic and transgenic HNC mouse models. From a national perspective, prior to joining Genentech, Dr. Raben served on the NRG Oncology head and neck steering committee for the past 15 years. He also served as the Developmental Therapeutics Co-Chair at the NRG over the past 6 years turning it into a full committee. In addition, he has served on the bi-annual ASTRO Multidisciplinary HNC Symposium planning committees and was the President of this meeting in 2014. Dr. Raben is an active member of the American Head and Neck Society and the AACR and served on the steering committee for the recently completed AACR-AHNS Head and Neck Cancer meeting in 2019. Dr. Raben is a long-standing member of IASLC. He actively serves as an ASCO Ambassador for Multidisciplinary Cancer Management Courses (MCMC) to help educate underserved areas internationally. He is an ad hoc reviewer for high impact journals such as Journal of Clinical Oncology, JAMA Oncology, Oral Oncology, Head and Neck, Int. Journal of Radiation Oncology Biology Physics, Clinical Cancer Research and Cancer Research and was an editor for the ASCO Daily News in 2018-2019. He has authored over 175 publications.

Srinivas Raman MD, MASc, FRCPC

Radiation Oncologist – Clinician Investigator, Princess Margaret Cancer Centre​
Assistant Professor, Department of Radiation Oncology, University of Toronto
Toronto, ON

Dr. Srinivas Raman is a staff radiation oncologist at the Princess Margaret Cancer Centre and an assistant professor in the department of radiation oncology, University of Toronto. Srinivas previously completed a bachelor’s and master’s degree in mechanical engineering, and medical school at University of British Columbia, followed by radiation oncology residency at University of Toronto. He received the 2018 CARO fellowship award to study knowledge-based methods for radiotherapy quality assurance in clinical trials, and undertook a clinical-research fellowship at BC Cancer Vancouver. His current research interests are in applying automation and artificial intelligence to clinical workflows.

Andrew Robinson, MD, FRCPC

Associate Professor of Medicine, Queens University
Medical Oncologist, Kingston General Hospital
Kingston, ON

Dr. Andrew Robinson is a medical oncologist, and  associate professor of Medicine at Queens University in Kingston, Ontario.  He attended medical school in Winnipeg, and Internal Medicine and Medical Oncology training in Vancouver, before  returning to Ontario to practice.  He has  Masters of Biotechnology from Johns Hopkins University – it was an online Masters – but still counts.   He works predominantly with lung cancer and GU cancers  patients in Kingston.   He also locums at various locations including Charlottetown PEI, Sudbury Ontario, and Sunnybrook (Toronto), Ontario,  and has gained first hand appreciation of institutional differences and variations in practice.   He is neither an expert nor a key opinion leader, but hopes to provide a fresh perspective to this talk.

Sarah Sample, MSW RSW

Clinical Social Worker in oncology
BC Cancer, Vancouver Cancer Centre
Vancouver, BC

Sarah has worked for over 25 years as a clinical social worker in oncology at the Vancouver Cancer Centre and is currently providing relief in semi-retirement. Prior to retirement, Sarah was the Professional Practice Leader in Patient and Family Counselling. She was a sessional Instructor at the School of Social Work & Family Studies, at the University of British Columbia. Sarah developed, implemented and has offered Mindfulness Based Stress Reduction (MBSR) courses for patients since 2000. She was awarded the Clinical Excellence Award from the Canadian Association of Psycho-oncology (CAPO) in 2017.  Sarah has been a co-investigator and collaborator on a number of research studies and articles within her field. She has authored two chapters in Surviving Cancer as a Family. Sarah is a current member of “Song-cology”, a BC Cancer choir made up of staff clinicians, researchers and members of the BC Cancer Foundation.

Devin Schellenberg, MD, FRCS(C)

Clinical Instructor, Radiation Oncologist
Department of Radiation Oncology
BC Cancer , Abbotsford Centre & Fraser Valley Centre
Vancouver, BC

Dr. Devin Schellenberg is a radiation oncologist practicing in the Fraser Valley and Abbotsford Cancer Centres. He is currently the head of the Clinical Trials Unit at the Abbotsford Cancer Centre and is one of the leaders in the British Columbia stereotactic radiation working group.

His radiation oncology residency was carried out at Princess Margaret Hospital in Toronto and the BC Cancer Agency, after which he completed a fellowship in stereotactic body radiation therapy at Stanford University in 2007.

His present research is focused on the use of novel imaging modalities in radiation therapy.

Heidi Schmidt, MD, FRCP(C)

Interim Radiologist-in-Chief, Toronto Joint Department of Medical Imaging
University Health Network, Sinai Health System, Women’s College Hospital
Professor of Radiology, University of Toronto
Radiology Quality Lead, High Risk Lung Cancer Screening, Cancer Care Ontario
Toronto, ON

Dr. Heidi Schmidt is Professor of Radiology at the University of Toronto, and the Interim Radiologist-in-Chief of the Joint Department of Medical Imaging at the University Health Network, Sinai Health and Women’s College Hospital.

She trained in Germany, where she graduated from Medical School in 1988, and finished her residency as a diagnostic radiologist in 1993. Following a research fellowship at the University of California, San Francisco (UCSF) in 1994, Dr. Schmidt was on faculty of the Department of Radiology at UCSF until she moved to Toronto in 2002. Since then, Dr. Schmidt is a staff radiologist in the Cardiothoracic Division in the JDMI.

After her recruitment to Toronto in 2002, her research focused on lung cancer screening using low-dose computed tomography, both as a site in the International Early Lung Cancer Action Program (I-ELCAP), as well as a site in the Pan-Canadian Early Lung Cancer Detection Study. Since 2017, Dr. Schmidt is the Radiology Quality Lead of the High Risk Lung Cancer Screening Pilot at Cancer Care Ontario.

For more than 10 years, from 2007-2018, Dr. Schmidt was the JDMI Site Director at Women’s College Hospital. For 6 years, she was also the head of the chest section in JDMI, before she became head of the cardiothoracic division in March 2016. In February 2018, she was appointed as interim radiologist-in-chief.

 

Yu Shyr, Ph.D., FASA, FAAAS

Harold L. Moses Chair in Cancer Research
Chairman, Department of Biostatistics
Director, Vanderbilt Center for Quantitative Sciences (VCQS)
Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design (VANGARD)
Professor of Biostatistics, Biomedical Informatics, Cancer Biology, and Health Policy
Vanderbilt University Medical Center
Nashville, TN

Yu Shyr received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine.  At Vanderbilt, he has collaborated on numerous research projects; assisted investigators in developing clinical research protocols; collaborated on multiple grants funded through external peer-reviewed mechanisms; and developed biostatistical and bioinformatic methodologies for clinical trial design, high-dimensional data analysis, and experimental design. 

Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS) and a US Food and Drug Administration (FDA) advisory committee voting member. He has published more than 470 peer-reviewed papers in a variety of journals (h-index = 100).  Dr. Shyr was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section.  Dr. Shyr was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. He is the Associate Editor for JAMA Oncology, Journal of Thoracic Oncology (JTO), and the Statistical Advisory Board Member for PLoS ONE. In addition, Dr. Shyr is the principle investigator of the NCI U01 grant of Barrett’s esophagus translational research network coordinating center (BETRNetCC). Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology including a series of papers on estimating the sample size requirements for studies conducting DNA and RNA sequencing analysis.

Stephanie Snow, MD, FRCPC

Associate Professor, Dalhousie University
Medical Oncologist, QEII hospital
Halifax, NS

Dr. Snow is a staff Medical Oncologist at the QEII hospital in Halifax, Nova Scotia and an Associate Professor at Dalhousie University. After pursuing undergraduate training at McGill, she completed her MD, Internal Medicine and Medical Oncology training at Dalhousie. She treats head and neck, thoracic and GI malignancies. Academically, she has a strong interest in Medical Education, overseeing the Dalhousie Undergraduate Medical Oncology program and contributing to national oncology education initiatives. She participates in clinical research locally in areas relevant to her treatment sites and also supportive care. ​

Erica Tsang, MD FRCPC

Medical Oncology Resident, BC Cancer
Vancouver, BC

Erica Tsang is a Medical Oncology resident at BC Cancer. She has a strong interest in cancer genomics, epidemiology, and public health.

Theodoros Tsakiridis, PhD, MD, FRCPC, 

Associate Professor
Mcmaster University
Pathology and Molecular Medicine
Hamilton, ON

Dr. Tsakiridis is a Radiation Oncologist and Scientist at the Juravinski Cancer Center in Hamilton, Ontario. He treats genitourinary and lung cancer and specialises in modern stereotactic radiotherapy and radiosurgery using robotic cyberknife and modern linear accelerator therapies. Dr Tsakiridis’ research includes basic science laboratory work, translational and clinical radiotherapy studies. His laboratory work aims to identify molecular pathways of oncogenes and tumour suppressor genes involved in radiation responses of cancer cells and preclinical radiation sensitizing therapies for lung and prostate cancer. His clinical research includes tumour and serum biomarkers of radiation response, clinical studies of radiosensitizers and development of stereotactic radiotherapy techniques.

John Yee, MD, FRCS(C)

Assistant Professor- Division of Thoracic Surgery, UBC
Director- Lung Transplant Program, VGH
Vancouver, BC

Dr. John Yee is an Assistant Professor-Division of Thoracic Surgery, UBC and Director- Lung Transplant Program, VGH.

Dr. Yee is a designate of the Chair of the UBC Department of Surgery for the Surgical Oncology Network Council Executive.

Kelly Zibrik, MScN, RN

Coordinator, Lung Tumor Group
BC Cancer
Vancouver, BC

Kelly Zibrik received her Bachelor in Science in Nursing degree from the University of British Columbia in 2002 and a Masters degree in Nursing from the University of Northern British Columbia in 2009. She has worked at  BC Cancer  since 2004 in various clinical nursing roles and is currently working as a nurse triage coordinator with the lung tumor group at the Vancouver Centre.